Rubik-like magnetic nanoassemblies as an efficient drug multifunctional carrier for cancer theranostics

Fei Xiong, Yuejian Chen, Jianxiang Chen, Bingya Yang, Yu Zhang, Huile Gao, Zichun Hua, Ning Gu

Abstract

A practical and effective strategy for loading hydrophobic anticancer agents within the inside and outside oleic acid layer of Rubik-like magnetic nanoassemblies (MNAs) is established. In this strategy, four individual oleic acid-capped iron oxide nanocubes and dioleate-modified polyethylene glycol are assembled into cluster with high drug loading capability, high magnetism, as well as rapid and extended release behavior. After loading model drug paclitaxel (PTX), PTX-MNAs show greater antitumor activity both in vitro cell culture and in vivo animal trials compared with the same dose of free PTX (Taxol). With high uptake by tumor cells, MNAs exhibit in tumor imaging by magnetic resonance imaging. These outstanding properties are largely due to the drug delivery systems that take high drug-loading capability and high magnetism into consideration in a nano-dimension for maximizing the nanotheranostic functions and minimizing the toxic side effects. In summary, the Rubik-like magnetic nanoassemblies may have the potential to realize “all-in-one” nanotheranostic strategy to detect, diagnose, treat, and monitor tumors and therapeutic response in further pre-clinical and clinical studies.

Keywords:
Iron oxide nanocubes
Magnetic nanoassemblies
Paclitaxel
Magnetic resonance image
Cancer therapy

1. Introduction

Short comings of currently conventional systemic chemotherapy include limited therapeutic efficacy, inability to produce and maintain a therapeutic concentration of drug into a localized pathological site, toxicity to non-targeted tissues and no means of simultaneous visible detection or imaging. The emergence of multifunctional magnetic nanoparticles these years attracted a great deal of attention and anticipation into the realm of cancer nano-theranostic modalities. Of the different types of magnetic nanoparticles, typically single spheres, surface engineered superparamagnetic iron oxide nanoparticles (SPIONs) have enabled better localized targeting of drugs, a means of visualization through magnetic resonance imaging (MRI) and an apoptotic effect on cancer cells through localized hyperthermia as a result of the magnetic properties in conjunction with the drug delivery component of the nanoparticles [1–4]. DESIRABLY, a high magnetic response is therefore essential in magnetism based multiple biomedical functions and is directly proportional to the size of the nanoparticle. However, although numerous chemical means of drug loading have been achieved, the ability to produce a large, rapid and controlled release of drug within therapeutic range is problematic in that higher drug loading capacity is related to particle surface area. Smaller particles provide more surface area and are therefore more suitable for drug loading but at the expense of magnetic properties. The challenge therefore was to construct a drug delivery system that combined a high drug loading capacity with greater magnetic properties in a nano-dimension for maximizing the theranostic properties of the system.

We propose a nano-carrier platform for delivering hydrophobic anticancer drugs to tumors through the formation of Rubik-like magnetic nanoassemblies (MNAs) utilizing a solvent-exchanging assembly procedure (Fig. 1). The nanoassemblies are multiple core/shell structures composed of hydrophobic oleic acid-capped magnetic Fe3O4 nanocubes (Fe3O4@OA NCs, core) and amphiphilic dioleate-modified polyethylene glycol (OA2-PEG, shell). Compared to spherical particles, cubes provide a greater surface area to volume ratio providing enhanced loading of small hydrophobic molecules in the OA layer for concentrated drug delivery. Magnetic dipole–dipole interactions of assembled nanoparticulate structures are much stronger than those of individual nanoparticles [4], therefore the aggregated SPIONs can provide even higher contrast than individually dispersed SPIONs as MRI contrast agent [5–10]. In some published literatures [5,6,11], the T2 relaxivity (r2) value of clustered nanoparticles can be more than 18-times higher than that of individual nanoparticles under the same iron concentration. Assembly of several smaller nanocubes into one cluster produces a greater magnetic response than the summation of each individual nanocubes. Cube clusters also provide for added surface area and greater drug loading as compared to a single larger cube. Although drug release from the outer exposed OA-layer of MNAs is rapid and constitutes a burst effect, the inner surfaces of adjacent cubes provide protection from the burst effect

© 2013 Elsevier B.V. All rights reserved.

Available online 2 October 2013
Accepted 24 September 2013
Received 30 May 2013
Article history:
Keywords:
and enable a higher concentration of drug to be released at a later time when the cubes have reached their targeted location. Hence rapid and sustained therapy can both be achieved in one nano-drug delivery system. To realize the effective delivery, the nanoassemblies must also possess other properties such as optimal hydrodynamic particle size, high hydrophilic surface for EPR (enhanced permeability and retention)-effect, remain in circulation sufficiently to reach the intended target and to escape being rapidly opsonized and massively cleared by the reticuloendothelial system (RES) of the liver and spleen as well as macrophages of mononuclear phagocyte system (MPS) tissues such as the lungs and the bone marrow.

In this paper, we used paclitaxel as model drug and constructed drug-loaded MNAs (PTX-MNAs). Compared with a commonly used commercial preparation of paclitaxel (Taxol), the results presented here show that multifunctional capacities within a single nanoassembled material have a number of potential applications in targeted drug delivery and MRI for tumor diagnosis and therapy in clinic.

2. Materials and methods

2.1. Materials and animals

Paclitaxel was purchased from Jiangsu Yew Pharmaceutical Co., Ltd. (Wuxi, China, purity > 99%). Taxol injection purchased from Yangtze River Pharmaceutical Group Jiangsu Pharmaceutical Trading Co., Ltd. (Jiangsu, China). Fluorescein (2-(6-hydroxy-3-oxo-3h-xanthen-9-yl)-benzoic acid, C20H12O5) was purchased from Aladdin Chemical Reagent Company (Wuhan, China). RAW264.7 and B16F10 cells were purchased from Shanghai Cellular Institute of China Scientific Academy (Shanghai, China). Apoptosis PI Detection Kit was purchased from KeyGen Biotech Co. Ltd. (Nanjing, China). Meso-2, 3-dimercaptosuccinic acid-coated γ-Fe3O4 nanoparticles were provided by our lab. 3-(4,5-Dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) was purchased from Fluka (MO, USA).

C57BL/6 mice were purchased from Shanghai Laboratory Animal Center of the Chinese Academy of Sciences and maintained at 22 ± 2 °C on a 12 h light–dark cycle with access to food and water ad libitum. The animals used for the experiment were treated according to the protocols evaluated and approved by the ethical committee of Nanjing University (Nanjing, China).

2.2. Preparation of PTX-MNAs

Fe3O4@OA NCs were synthesized through the decomposition of iron-oleate complexes at 300 °C using octadecene as the solvent by previously developed methods [12]. OA2-PEG with PEG number average molecular weight of 2000 was synthesized through lysine linkage and esterification following the published procedure [13]. For preparation...
of PTX-MNAs, PTX, Fe₃O₄@OA NCs and OA₂-PEG were dissolved in tetrahydrofuran (THF) at a weight ratio of 1:5:55 under sonication. The mixture was slowly added into double distilled water under sonication in an ice water bath and the resulting suspension was stirred for 6 h to evaporate THF. Then the suspension was dialyzed against water to remove the remaining drug. The loading of drug in PTX-MNAs was 12 wt.% (PTX/Fe).

2.3. Characterization

The morphological structure of PTX-MNAs dispersed in double distilled water was analyzed using TEM with negative staining by 2% phosphotungstic acid. The hydrodynamic diameter, size distribution and zeta potential of PTX-MNAs were examined using TEM and Zeta PALS instrument (Brookhaven Instrument Corporation) by dynamic light scattering (DLS) and electrophoretic mobility at 25 °C. To determine the kinetics of PTX release from particles, 1 mL of PTX-MNAs was added to 1 mL fresh rat plasma and the mixture was placed in dialysis bag (8000–10000 molecular weight cutoff). The dialysis bag was immersed in 100 mL of pH 7.4 phosphate buffer or pH 4.5 acetate buffer (both of release medium containing 0.5% v/v Tween 80) shaken continuously at 37 °C. One milliliter aliquots of release medium were removed and the same volume of fresh medium was added periodically. Twenty-microliter aliquots of the released drug were quantified at 227 nm by HPLC using a reverse-phase C18 column (250 mm × 4.6 mm, 5 μm particle size; Hanbon Sci. & Tech., Huaian, China), with methanol–water (75:25, v/v) as mobile phase at 40 °C at a flow-rate of 1.0 mL/min. Magnetic properties were measured with a vibrating sample magnetometer (VSM, Lakeshore 7407, USA) in a field up to 5 kOe.

2.4. Determination of drug in biosamples

Quantification of drug in cells, plasma, tumors and tissues was performed as follows. Cells were sonicated in 1 mL of acetonitrile and centrifuged at 16,000 rpm at 4 °C for 10 min. The supernatant obtained was analyzed for drug uptake in cells using HPLC. A 100 μL aliquot of homogenate (20%, w/v) of tumors or tissues in physiological saline was added into 1 mL fresh rat plasma and the mixture was placed in a冰 water bath and the resulting suspension was stirred for 6 h to evaporate THF. Then the suspension was dialyzed against water to remove the remaining drug. The loading of drug in PTX-MNAs was 12 wt.% (PTX/Fe).

2.5. In vitro performance of PTX-MNAs

2.5.1. Uptake of vehicles by macrophage cells

RAW 264.7 cells were seeded in 24-well plates at density of 1 × 10⁵ cells per well and left overnight. After exposure to MNAs at concentrations of 50, 100, and 200 μg Fe/mL in medium at 37 °C for 1 h, some cells were washed, dissolved and analyzed for iron levels using 1,10-phenanthroline colorimetric method. Other cells were fixed with 2.5% glutaraldehyde and stained by Prussian blue (4% potassium ferri-ferrocyanide in 4% HCl) and nuclear fast red, which indicates the presence of iron and cell nuclei. Then cells were washed and visualized for vehicle internalization using light microscopy (Axioplan Imaging II, Zeiss, Göttingen, Germany). The cells without being incubated with MNAs were observed as control.

2.5.2. Penetration and cytotoxicity of PTX-MNAs in melanoma cells

B16F10 cells were seeded in 6-well plates and allowed to adhere overnight. The medium was then replaced with 2 mL medium containing 1.0, 2.0 and 4.0 μg PTX/mL of Taxol (Yangtze River Pharmaceutical Group Jiangsu Pharmaceutical Trading Co., Ltd., China), PTX-MNAs in the absence and presence of neodymium–iron–boron (NdFeB) permanent magnet (remanence Br = 0.52 T) placed beneath the cell plates incubated for 4 h. After centrifugation of detached cells, the precipitation was disposed and analyzed for drug concentration using HPLC as mentioned below and for iron levels using 1,10-phenanthroline colorimetric method. Cell viability was evaluated according to mitochondrial conversion by using a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT).

To assay the penetration and MRI efficiency of vehicles in vitro, B16 F10 cells incubated for 4 h with 4 μg/mL of PTX-MNAs in the absence and presence of a magnet were washed, trypsinized and resuspended in 2% agarose solution for imaging on a clinical 1.5 Tesla MRI scanner (Magnetom Avanto, Siemens, Germany) with a 12-channel head coil at room temperature. Water and cells incubated with Taxol were also tested as control. The sequence included a fast spin-echo sequence: repetition time (TR) = 5500 ms, echo time (TE) = 100 ms; field of view (FOV) = 50 mm × 50 mm; slice thickness = 2 mm.

2.6. In vivo theranostic effects

2.6.1. In vivo antitumor efficacy of PTX-MNAs

C57BL/6 mice (6–8 weeks of age) were implanted subcutaneously in the left flank with B16F10 cells (10⁵ cells/mouse) in 0.2 mL PBS. When the mean volume of melanoma tumor reached 200–300 mm³, the mice were divided into four groups and administered by a single tail vein injection of one of the following samples: saline (0.9% sodium chloride), Taxol injection (10 mg PTX/kg), and PTX-MNAs (10 mg PTX/kg) in the absence of a NdFeB permanent magnets and in the presence of a magnet placed over the tumor for 0.5 h (PTX-MNAs-M) after injection under anesthesia. Five mice were killed by cervical vertebral dislocation at one day after injection, and their tumors were harvested and measured with vernier calipers. Another five mice were used for daily monitoring tumor measured individually. At day 8 after injection, these five mice were killed and their tumors were processed and analyzed. The remaining five tumor-bearing mice in each group were checked for survival analysis every day. The tumor volumes were calculated using the formula: (the largest diameter) × (the smallest diameter)² × 0.5. Therapeutic effects on tumor growth were expressed as the ratio of mean tumor volume in treated mice (T) divided by that of control group (C) versus time and tumor inhibition rate (TIR), which was calculated by the following formula: TIR (%) = (tumor volume of saline group — tumor volume of drug group)/tumor volume of saline group. Apoptosis was determined with the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) assay for the identification of double-stranded DNA breaks with an in situ cell death detection kit according to the manufacturer's instructions.

2.6.2. In vivo MRI in tumor-bearing mice

At 2 h after injection, mice were anesthetized and placed in the center of a clinical 1.5 Tesla MRI scanner (Magnetom Avanto, Siemens, Germany). The sequence was the same as that mentioned above except for FOV = 14 cm × 14 cm. The signal intensities of PTX-MNAs-incubated cells or injected mice in the absence and presence of magnets were determined from a circular 10-mm² region of interest (ROI).
2.7. Pharmacokinetics and biodistribution of PTX-MNAs in tumor-bearing mice

At 0.25, 0.5, 1, 2, 4, 8, 12 and 24 h after injection, the three animals of each group were sacrificed under ether anesthesia. Blood was collected in heparin-coated tubes and centrifuged at 1500 rpm for 5 min. Tumor, liver and kidneys were removed, weighed and homogenized in physiological saline. To further evaluate efficiency of tumor targeting, the areas under the plasma and tissue concentration–time curves (AUC) of PTX-MNAs or PTX-MNAs-M were divided by the AUC of Taxol in certain tissue. Re relative exposure (Re) was expressed as follows: Re_{PTX-MNAs} = AUC_{PTX-MNAs} / AUC_{Taxol}, Re_{PTX-MNAs-M} = AUC_{PTX-MNAs-M} / AUC_{Taxol}. The vehicle distribution in tumors and tissues was also visualized by Prussian blue staining. The subcellular localization of vehicles in tumors was examined with TEM.

2.8. Safety assay

To study the toxic effects of PTX-MNAs treatment, 24 healthy mice (body weight = 18–22 g) were randomly divided into 4 groups (6 mice per group, free access to food and water) and administered three doses on days 0, 4, and 8 through tail vein injection of one of the following samples: saline, Taxol injection (10 mg PTX/kg), and PTX-MNAs (10 mg PTX/kg) in the absence and presence of a magnet placed on the left side of flank for 0.5 h after injection under anesthesia. The body weight was recorded daily and tissue sections were prepared for histopathological analysis. In details, on day 12 (4 days after last administration), the liver and kidneys were harvested and processed routinely into paraffin, sectioned at a thickness of 5 μm, and stained with haematoxylin and eosin (HE) staining.

3. Results and discussion

3.1. Preparation and characterization of PTX-MNAs

Although encapsulating antitumor drug into magnetic nanoparticles has shown promise as a means of achieving multifunctional theranostics of tumors in animal models, the possibilities of combination of high drug-loading capability and high magnetism together into one nano-sized depot had not been explored. This is the first report about the use of Rubik cube-like magnetic assemblies as a drug delivery system. The strategy of developing PTX-loaded MNAs using a solvent-exchanging assembly procedure was shown schematically in Fig. 1. Although the drug is not chemically conjugated to Fe3O4@OA NCs, strong hydrophobic interactions with the OA layer of the Fe3O4@OA NCs trap the drug within the nanoparticles, preventing its rapid leaching, making the MNAs a promising candidate for tumor long-lasting therapy. Monodispersed Fe3O4@OA NCs provide fixed dimension for drug loading and thus decrease the difference of drug-loading efficiency between batches.

Physical properties of the PTX-MNAs following the solvent-exchanging assembly procedure were revealed by transmission electron microscopy (TEM). The TEM of Fe3O4@OA NCs dispersed in n-hexane was shown in Fig. 2A. Four individual Fe3O4@OA NCs with 10.2 ± 0.7 nm diameter were assembled into PTX-MNAs, and the average size of assemblies and its shell were 40–50 nm and 2–3 nm, respectively (Fig. 2B). The hydrodynamic diameter of PTX-MNAs measured by dynamic light scattering (DLS) was 61.9 ± 2.0 nm (Fig. 2C), which was the total diameter of an assembly and its aqueous layer thickness. The hydrodynamic diameter is small enough to penetrate into the tumor tissues according to the reported size range of 20–200 nm in which nanocarriers could extravasate and accumulate maximally to distal tumor sites following intravenous injection via the EPR effect [11].

The drug release rate from nanoassemblies in the presence of fresh rat plasma was affected by release time and the pH value of release medium (Fig. 2D). The external exposed surfaces of PTX-MNAs to systematic circulation environment resulted in faster drug release, while the internal adjacent surface hidden from systematic circulation environment resulted in slower drug release. Consistently, about 43% of total drug was released in the former 48 h of incubation, while about only 16% drug of total drug was release in the latter 48 h, thus indicating rapid–released and sustained released drugs were both realized in this system. After 96 h of incubation, 65.73 ± 2.82% of total drug was released in the medium at pH 4.5 compared with the 52.57 ± 3.18% released in the medium at pH 7.4, suggesting that after internalization into tumor cells, the acidic environment in endolysosome might benefit the release of PTX from nanoassemblies. PTX generally behaves as a weak organic alkaline and is more soluble in an acid than in an alkaline environment, therefore PTX-MNAs released the drug in a pH-dependent manner.

In addition, assembly of several magnetic nanocubes into one cluster is effective to prepare MRI probe with high relaxivity for tumor detection. The hysteresis loop of assembled PTX-MNAs is shown in Fig. 2E and the saturation magnetization (Ms) value of assembled PTX-MNAs is 69.90 emu/g. Magnetic measurements indicated superparamagnetic behavior of PTX-MNAs at room temperature, as evidenced by zero coercivity and remanence on the magnetization loops and the Ms of PTX-MNAs was enough to be used as MRI probe. The high magnetic response of cluster is also a guarantee for enhanced magnet-mediated intracellular drug uptake with applying an external magnetic field, and the assembled Fe3O4@OA NCs are thus better suited for magnetic-induced targeting in the next research.

3.2. In vitro performance of PTX-MNAs

3.2.1. Effects of surface molecular phagocytosis by RAW 264.7 macrophage cells

RAW 264.7 cells are a kind of macrophage cells. Fe3O4 NPs can be made to evade RES, MPS and attain a long blood circulation time to reach other target organs by PEG coating. To assess the ability of OA2-PEG-coated MNAs to escape macrophage (RES and MPS) uptake, in vitro phagocytosis experiments were conducted using RAW 264.7 cells prior to in vivo studies. To assess the impact of surface coating on uptake, cells were also exposed to small molecular meso-2, 3-dimercaptosuccinic acid-coated Fe3O4 nanoparticles (Fe3O4@DMSA NPs) with similar diameter [14]. Most of the RAW 264.7 cells incubated with 100 pg/mL of Fe3O4@DMSA NPs for 1 h exhibited blue staining, while few blue spots were detected in the cytoplasm of the cells incubated with polymer coated-MNAs under the same conditions (Fig. 3A). Based on this approach, OA2–PEG coating can effectively prevent the uptake of iron oxide nanoparticles by macrophages, and can achieve long circulation in blood stream and shield for nanoparticles from being rapidly opsonized and massively cleared by RES and MPS (liver, spleen, lungs and bone marrow) rich organs before reaching tumor.

3.2.2. In vitro cellular penetration and cytotoxicity of PTX-MNAs

PTX is a mitotic inhibitor used in cancer chemotherapy, including ovarian cancer, breast cancer, melanoma and so on in clinic. B16F10 cells are a kind of malignant melanoma cells. Therefore, we used B16F10 melanoma cells as a model cell to study the extent of drug penetration and cytotoxicity in vitro after loading PTX into MNAs and investigate whether PTX-MNAs were effective against an established melanoma in vivo. The extent of drug penetration and cytotoxicity was demonstrated on B16F10 melanoma cells by loading PTX into MNAs. The cellular PTX content increased strongly after exposure of the cells to PTX-MNAs from 0.49 ± 0.13 to 1.30 ± 0.17 pg/cell compared with cells exposed to the same concentration of Taxol (0.28 ± 0.07 to 0.80 ± 0.15 pg/cell) (Fig. 3B). To study the effects of an external magnetic field on the intracellular accumulation of PTX-MNAs, the cells were incubated with the same concentration of PTX-MNAs in the presence of a magnet (PTX-MNAs-M) underneath the cells. The cellular PTX values were significantly (0.53 ± 0.14 to 1.48 ± 0.26 pg/cell)
higher than those obtained by incubations without a magnet. These experiments demonstrate that MNAs could facilitate intracellular delivery of PTX into B16F10 cancer cells and the magnetic feature can be exploited to optimize the cellular uptake. The IC50 values determined by MTT method were 86.3 ± 5.2 ng/mL, 54.8 ± 4.6 ng/mL, and 39.6 ± 5.7 ng/mL for Taxol, PTX-MNAs and PTX-MNAs-M, respectively. It was worth noting that the corresponding excipient concentration of PTX-MNAs was almost not toxic to the B16F10 cells, while the corresponding Cremophor/ethanol carrier mixture of Taxol significantly affected the viability of cells (data not shown). These results suggest that it does not only maintain the cancer cell destruction ability of PTX, but also efficient delivery of drug to the cells and more effective in the presence of a magnet.

Using a clinical 1.5-T MRI scanner, the mean T2 relaxation time of B16F10 cells in agarose incubated with PTX-MNAs and PTX-MNAs-M (Fig. 3C) was significantly decreased (425.2 ± 21.5 and 336.4 ± 19.3 ms, respectively) compared with water and cells incubated with Taxol (no MR contrast). The results indicated the potential of MNAs to serve as a sensitive MRI contrast agent.

3.3. In vivo theranostic effects

3.3.1. Antitumor effect of PTX-MNAs in the B16 F10 melanoma-bearing C57BL/6 mice

To investigate whether PTX-MNAs were effective against an established melanoma in vivo, B16F10 cells were injected subcutaneously into C57BL/6 mice. On day 0, the mice were injected intravenously in single dose with saline (0.9% sodium chloride), Taxol (10 mg PTX/kg), PTX-MNAs (10 mg PTX/kg) and PTX-MNAs-M (a magnet placed over the tumor for 0.5 h after injection under anesthesia, 10 mg PTX/kg). On day 8, the tumors in mice treated with PTX-MNAs-M were much smaller.
than in comparison with the other three groups (Fig. 4A), and the tumor inhibition rates (TIR%) of Taxol, PTX-MNAs and PTX-MNAs-M group were 58.67%, 70.73% and 78.74%, respectively. In a Kaplan–Meier curves (Fig. 4B), the mean survival time of PTX-MNAs-M group was 21.6 days compared with 19 days for PTX-MNAs group, 15.6 days for Taxol group, and 13.6 days in the saline control group. To evaluate apoptotic effects within the tumor cell isolated from mice melanoma models, TUNEL assay was used to detect DNA fragmentation. The results shown in Fig. 4C (arrows) illustrate increased apoptotic events following treatment with PTX-MNAs, especially in the presence of an external magnetic field. These results indicate that PTX-MNAs repressed tumor growth and prolonged the mice survival to a greater extent than Taxol, and PTX-MNAs-M exhibited the strongest antitumor activity and the longest mean survival time.

Based on these, the increased cellular toxicity, increased apoptosis events and decreased tumor size could be further explained by the intracellular localization to acidic environment within lysosomes where more drug is released from MNAs than that in neutral environment of blood and other tissues.

3.3.2. In vivo MRI

To assess the application potentials of PTX-MNAs in tumor imaging and accumulation ability of vehicles in tumor-bearing mice, the MRI of mice treated with PTX-MNAs and PTX-MNAs-M was conducted at 2 h post-injection with dose of 10 mg PTX/kg via tail vein. For Taxol-treated control group, no significant decrease of MRI signal intensity in tumor area is observed (Fig. 5, control, arrow, T2 value = 441.4 ± 13.7 ms), whereas the signal intensity in the tumor of mice treated with PTX-MNAs and PTX-MNAs-M dropped dramatically (T2 value = 304.4 ± 42.7 and 223.1 ± 33.7 ms, respectively). These results indicate that the MNAs-based drug carriers produce a significant difference of imaging contrast after extravasating through leaky neo-vasculature of tumor tissue. The contrast-enhanced imaging can potentially enhance the efficacy of early diagnosis and timely therapeutic intervention.

3.4. Pharmacokinetics and biodistribution of PTX-MNAs

To investigate the basis of the increased effectiveness in tumor growth suppression and reduced toxicity, we determined the pharmacokinetics and distribution of PTX in the systemic circulation, tumor and other tissues. The C57BL/6 mice bearing B16F10 tumors were
injected intravenously with 10 mg/kg of Taxol, PTX-MNAs, and PTX-MNAs-M, and the PTX levels in biosamples were determined by high performance liquid chromatography (HPLC). The advantages of MNAs carrier for drug circulation in plasma were very obvious (Fig. 6A): PTX in Taxol has a short biological half-life (distribution phase $t_{1/2(\alpha)}$ of 0.47 h, elimination phase $t_{1/2(\beta)}$ of 2.14 h) and rapid elimination rate ($Cl_\alpha = 354.51 \text{ mL/(kg·h)}$) from the plasma. Loading PTX into MNAs produced a significant change in pharmacokinetic parameters: the PTX-MNAs were more slowly removed from plasma compared with Taxol. The elimination phase ($t_{1/2(\beta)} = 3.63 \text{ h}$) and mean residence time ($MRT = 6.82 \text{ h}$) of PTX-MNAs were 1.7 and 2.2 times longer than those of Taxol, respectively. The area under curve (AUC), elimination rate constant ($k_{10}$) and $Cl_\alpha$ values also confirmed this trend. An interesting observation was: intravenous administration of PTX-MNAs in the presence of a magnet placed over the surface of mice was also beneficial to increasing amount and prolonging retention time of drug in plasma. There are considerable increases in $t_{1/2(\beta)}$, AUC and MRT parameters and decreases in $k_{10}$ and $Cl_\alpha$ under magnetic field application. Correspondingly, the volume of distribution $V_c = 173.02 \text{ (mL/kg)}$ decreased substantially.

In order to evaluate biodistribution of PTX-MNAs in tumor and other tissues compared with Taxol, some targeting parameters were analyzed in this study [13]. In vivo tumor targeting studies displayed variable drug uptake capacity of tumor with different preparations: Re values of PTX-MNAs for plasma and tumor were 1.89 and 2.06, respectively, indicating that the exposure of PTX to plasma and tumor was significantly increased by entrapment of drug into MNAs. Further increase in the Re value caused by application of a magnet over the surface of a tumor was realized: the Re values of PTX-MNAs-M group for plasma and tumor were 2.55 and 3.07, respectively. On the basis of the above results, it can be concluded that encapsulation of PTX into MNAs could improve the drug distribution in plasma and tumor under the same administration dosage as Taxol, and application of an external magnetic field could further increase retention time and accumulation of drug in blood and tumor. The increase was considerable and would induce a better therapeutic effect in tumor diseases.

To further confirm the distribution of vehicles in normal and tumor tissues, Prussian blue staining was performed on tissue sections (Fig. 6B). We found high levels of Prussian blue-positive cells in the liver of the mice that administrated with PTX-MNA. However, liver tissue sections from the group that received PTX-MNAs-M had fewer positive cells. We did not detect iron oxide nanoparticles in the tissue sections of the kidneys from mice injected with either PTX-MNAs or PTX-MNAs-M. TEM provides an even higher resolution and showed the intracellular localization of iron oxide nanoparticles in the cells of tumor tissues (Fig. 6C). Vehicles were internalized within the cell inside cytoplasm and lysosomes. No uptakes of vehicles into mitochondria, endoplasmic reticulum and structures of the Golgi organ or the nucleus were found.

3.5. Safety assay

The changes in body weight and morphological analysis of HE-stained liver and kidneys of healthy mice, which were administered three doses on days 0, 4, and 8 through tail vein, were used as safety...
The body weights of mice recovered after cessation of drug treatment and no statistically significant differences in the body weight were observed between the treated mice and saline-injected mice (Fig. 7A). Histological slices in liver and kidneys (Fig. 7B) revealed that PTX-MNAs and PTX-MNAs-M did not cause any inflammatory response, degeneration or necrosis, suggesting the low toxicity of PTX-MNAs in the absence and presence of a magnet. Considered together, PTX-MNAs or PTX-MNAs-M treatment did not induce any apparent toxicity in mice.

4. Conclusions

In summary, we used a simple solvent-exchanging assembly method to load hydropobic anticancer agents within the inside and outside OA layer of Rubik-like MNAs with rapid and extended release behavior. Assembly of individual nanocube into cluster with high drug loading capability and high magnetism is an effective way to prepare multifunctional theranostic device. These results of cells and animal experiments, as well as the imaging data, suggest that significant portions of magnetic nanoassemblies are retained in the tumor after external magnetic field removal and the Rubik-like MNAs in combination with PTX can be effective in reducing tumor size compared with the same dose of free PTX (Taxol). The MR contrast-enhanced imaging can potentially diagnose, treat, and monitor tumors and therapeutic response in further pre-clinical and clinical studies.

Acknowledgments

This work was financially supported by National Basic Research Program of China (No. 2011CB933503), National Natural Science Foundation of China (No. 81001412 and 30870689), School of Pharmacy, Fudan University & The Open Project Program of Key Lab of Smart Drug Delivery (Fudan University), Ministry of Education, China and; The Open Project Program of State Key Laboratory of Pharmaceutical Biotechnology (KF-GN-201107), Nanjing University.

References


